期刊文献+

BSD2000深部热疗联合化疗治疗局部晚期胰腺癌患者的临床观察 被引量:3

Clinical observation of BSD2000 deep hyperthermia combined with chemotherapy in patients with advanced pancreatic cancer
原文传递
导出
摘要 为探讨BSD2000深部相控阵聚能热疗系统(BSD2000)联合化疗治疗局部晚期胰腺癌患者的近期疗效、疼痛及生活质量改善和不良反应,收集2009年10月至2014年10月在北京医院肿瘤内科确诊的30例局部晚期胰腺癌患者,给予化疗同时联合局部热疗的治疗方法(联合组),同时选取同期住院治疗30例局部晚期胰腺癌患者,仅给予单纯化疗作为对照组(化疗组),评估两组治疗效果及不良反应,观察两组在生活质量及疼痛改善方面有无差异。结果显示,联合组和化疗组的有效率和疾病控制率分别为10%、6.7%和83%、76%,两组相比无统计学差异(P>0.05),联合组治疗后疼痛及生活质量的改善均明显优于化疗组,差异具有统计学意义(P<0.05)。骨髓抑制和胃肠道反应是最常见的不良反应,两组相比发生率无明显差异(P>0.05),热疗与化疗联合并不增加毒副反应,两组均无严重不良反应发生。结果表明,在化疗基础上联合热疗可以明显减轻疼痛症状,提高患者的生活质量,且治疗简单,副作用较小,临床可操作性好,值得推广。 This study aims to evaluate the short-term efficacy, pain reduction, quality of life (QQL) and toxicity of BSD2000 deep hyperthermia combined with chemotherapy in patients with advanced pancreatic cancer. All cases were diagnosed and treated in Beijing Hospital from October 2009 to October 2014. A total sixty patients with advanced pancreatic cancer were divided into two groups. Thirty patients in the combination therapy group received chemotherapy combined with BSD2000 deep hyperthermia(twice per week). Another thirty patients in the chemotherapy therapy group were only given chemotherapy. Twenty-one days were one cycle. The short-term efficacy, pain relief, QQL and toxicity were evaluated after two cycles. All sixty patients were assessable for response. The response rates for the combination therapy group and the chemotherapy therapy group were 10% and 6.7%, respectively, while the disease control rates for the two groups were 83% and 76%, respectively. There was no significant different between the two groups (P〉0.05). The combination group showed significant improvement in pain relief and QQL compared to the control group (P〈0.05). There were some mild side effects, such as gas trointestinal toxicities and myelosuppression, but no significant difference between the two groups (P〉0.05). There was no severe side effect in the two groups. Even though there was no difference in efficacy, the combination group did show pain reduction, improved QQL and tolerable toxicity. BSD2000 deep hyperthermia combined with chemotherapy in patients with advanced pancreatic cancer is worthily recommended in the clinical application.
出处 《科技导报》 CAS CSCD 北大核心 2015年第12期72-76,共5页 Science & Technology Review
关键词 胰腺癌 化疗 热疗 疼痛和生活质量 advanced pancreatic cancer hypertherapy chemotherapy pain and life-quality
  • 相关文献

参考文献12

  • 1Wang P, Meng Z Q, Chen Z, et al. Survival rate of pancreatic cancer in elderly patients[J]. Hepato-gastroenterology, 2008, 55(82/83): 681-686.
  • 2余一祎,刘天舒.晚期胰腺癌姑息性化疗进展[J].中国癌症杂志,2009,19(8):585-589. 被引量:5
  • 3Wust P, Hidebrandt B, Streenivasa G, et al. Hyperthermia in combined treatment of cancer[J]. Lancet Oncology, 2002, 3(8): 489-497.
  • 4Trotti A, Bentzen S M. The need for adverse effects reporting standards in oncology clinical trials[J]. Journal of Clinical Oncology, 2004, 22(1): 19-22.
  • 5孙燕,周际昌.临床肿瘤内科学[M].北京:人民卫生出版社,1997.198-199
  • 6张太平,王天笑,赵玉沛.胰腺癌诊断和治疗的瓶颈与对策[J].中华消化外科杂志,2012,11(1):41-44. 被引量:20
  • 7Burris H,Moore M J,Anderson J, et al. Improvements in survival and clinical benefit with gemcitabine as first--line therapy for patients with advanced pancreas cancer: A randomized trial[J]. Journal of Clinical Oncology, 1997, 5(6): 2403-2413.
  • 8Herrmann R, Bodoky G, Ruhstaller T, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: Arandomized, muhicenter, phase lll trial of the Swiss Group for clinical cancer research and the central european cooperative oncology group[Jl. Journal of Clinical Oncologv, 2007, 25(16): 2212-2217.
  • 9Maluta S, Schaffer M, Pioli F, et al. Regional hyperthermia combined with chemoradiotherapy in primary or recurrent locally advanced pancreatic cancer: An open- label comparative cohort trial[J]. Strahlentherapie and Onkologic, 2011, 187(10): 619-625.
  • 10Yasuda M, Kondo M, Kokura S, et al. Comparison of concomitant gemcltahine chemotherapy and local hyperthermia, gemcitabine monoche motherapy, and local hyperthermia monotherapy for inoerable progressive pancreatic cancer[J]. Journal of Clinical Oncology, 2008, 26(Suppl 1): 15672.

二级参考文献24

  • 1杨红,钱家鸣,张惠广,郭涛.胰腺癌300例临床特点分析[J].基础医学与临床,2007,27(7):815-818. 被引量:8
  • 2Jemal A,Bray F,Center MM,et al.Global cancer statistics.CA Cancer J Clin,2011,61 (2):69-90.
  • 3Pappas S,Federle MP,Lokshin AE,et al.Early detection and staging of adenocarcinoma of the pancreas. Gastroenterol Clin North Am,2007,36(2):413-429.
  • 4Kim BJ,Lee KT,Moon TG,et al.How do we interpret an elevated carbohydrate antigen 19-9 level in asymptomatic subjects? Dig Liver Dis,2009,41 (5):364-369.
  • 5Gold DV,Modrak DE,Ying Z,et al.New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis. J Clin 0ncol,2006,24(2):252-258.
  • 6Van der Gaag NA,Rauws EA,van Eijck CH,et al.Preoperative biliary drainage for cancer of the head of the pancreas.N Engl J Med,2010,362(2):129-137.
  • 7Butturini G,Stocken DD,Wente MN,et al.Influence of resection margins and treatment on survival in patients with pancreatic cancer:meta-analysis of randomized controlled trials.Arch Surg,2008,143(1):75-83.
  • 8Tomlinson JS,Jain S,Bentrem DJ,et al.Accuracy of staging node-negative pancreas cancer:a potential quality measure.Arch Surg,2007,142 (8):767-774.
  • 9Pedrazzoli S,DiCarlo V,Dionigi R,et al.Standard versus extended lymphadenectomy associated with panereatoduedeneetomy in the surgical treatment of adenocarcinoma of the head of the pancreas:a multicenter,prospective,randomized study.Lymphadenectomy Study Group.Ann Surg,1998,228(4):508-517.
  • 10Evans DB,Farnell MB,Lillemoe KD,et al.Surgical treatment of resectable and borderline resectable pancreas cancer:expert consensus statement.Ann Surg Oncol,2009,16(7):1736-1744.

共引文献23

同被引文献23

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部